The HER2+ breast cancer subtype is defined by assessment of HER2 expression by immunohistochemistry (score 3+ or 2+ with positive ISH), and the standard of care treatment is trastuzumab, a monoclonal antibody directed to the HER2 molecule [12], which is administered based on the results of HER2 expression. The gene discussed is ERBB2; the disease is breast cancer.